THE CHROMOSOME | Clinical Content Series
Prediabetes
Back to Case Studies ArchiveCase Study
She was 39 years old and had been told at a routine blood test that her fasting glucose was slightly elevated, 108 milligrams per decilitre. Her physician had told her this was borderline, that she should watch her diet, reduce her sugar intake, and come back in a year. She had been given no further explanation. No investigation of why her glucose was elevated. No assessment of her insulin level. No evaluation of her metabolic risk profile. No discussion of what borderline actually meant for her biological future.
She had followed the advice conscientiously. She had reduced her sugar. She had walked more. She had returned a year later with a fasting glucose of 114. Her physician had repeated the same advice with slightly more emphasis and sent her home again.
She came to me two years after that first borderline result. Her fasting glucose was now 121. Her HbA1c was 6.1 percent, sitting precisely at the upper boundary of the prediabetic range, one decimal point from a formal diabetes diagnosis. She had gained 11 kilograms across those two years. Her fatigue had worsened. She had developed a persistent brain fog that she had attributed to stress and poor sleep, which were real, but were not the primary cause of what she was experiencing.
She had been watching the door to diabetes open slowly, millimetre by millimetre, for two years. And she had been told to watch her diet while it did.
This is the clinical tragedy of prediabetes management in Pakistan. Prediabetes is not a warning sign that something might happen. It is a confirmation that something is already happening, that the metabolic failure driving toward type 2 diabetes is already in progress, already causing damage, and already extracting a biological cost that manifests long before the formal diabetes diagnosis arrives. The vascular damage of diabetes does not begin at the moment of diagnosis. It begins in the prediabetic state, in the years of elevated insulin, chronic inflammation, and glucose toxicity that precede the fasting glucose crossing the arbitrary threshold that triggers a diagnosis.
When I evaluated her fully the picture was entirely consistent with what I find in the majority of Pakistani women presenting at this stage. Her fasting insulin was profoundly elevated, four times the upper limit of normal, while her glucose was only mildly elevated, because her pancreas was still compensating heroically, producing massive quantities of insulin to force glucose into resistant cells. This compensatory hyperinsulinaemia is the metabolic reality of prediabetes, and it is the most important number in the entire clinical picture, more important than the glucose, more important than the HbA1c. It tells you how hard the pancreas is working. It tells you how long it can sustain that work before it begins to fail. And it tells you exactly how much biological time remains before the prediabetes becomes irreversible diabetes.
Her fasting insulin told me she had perhaps two to three years of pancreatic reserve remaining if nothing changed. Nothing had been changing for two years because nobody had measured the number that mattered.
The FTO gene's influence on pancreatic beta cell function and insulin sensitivity creates a prediabetic trajectory in Pakistani patients that is faster, steeper, and more metabolically damaging than Western clinical models anticipate. Pakistani patients convert from prediabetes to type 2 diabetes at higher rates and over shorter time periods than European populations at equivalent glucose levels, because the genetic predisposition reduces the metabolic buffer available and accelerates beta cell exhaustion under the sustained demand of compensatory hyperinsulinaemia.
We did not watch and wait. We intervened comprehensively and immediately. We treated her insulin resistance as the urgent biological priority it was. We reduced her visceral fat, which was driving the inflammatory suppression of her insulin signalling. We recalibrated her cortisol pattern, which had been driving overnight hepatic glucose overproduction. We addressed her thyroid conversion impairment. We deployed targeted nutritional and peptide based interventions to support pancreatic beta cell recovery and reduce the compensatory insulin demand on a system that was approaching its limits.
Ten months later her fasting glucose was 92, completely normal. Her fasting insulin had fallen to within the normal range for the first time in years. Her HbA1c was 5.4 percent. She had lost 14 kilograms.
She had not progressed to diabetes. She had regressed to metabolic health. And she had done it in ten months, because someone had finally treated the condition she had rather than watching the number that described it.
FAQs
Prediabetes is a metabolic state in which blood glucose is elevated above normal but below the threshold of formal diabetes diagnosis, and it is far more clinically significant than the term borderline suggests. The vascular, neurological, and metabolic damage associated with diabetes does not begin at diagnosis. It begins in the prediabetic state, driven by the chronic insulin resistance, compensatory hyperinsulinaemia, and systemic inflammation that precede glucose elevation by years. Pakistani patients with prediabetes are already experiencing accelerated cardiovascular risk, early kidney stress, cognitive impairment, and progressive metabolic deterioration. The watch and wait approach that characterises Pakistani prediabetes management is not conservative medicine. It is a clinical failure that allows a reversible condition to become an irreversible one.
Fasting insulin. While Pakistani physicians focus almost exclusively on fasting glucose and HbA1c, the outputs of the metabolic failure, fasting insulin reveals the biological process driving those outputs. In prediabetes, fasting insulin is almost always severely elevated because the pancreas is compensating heroically for insulin resistance by producing massive quantities of insulin to maintain glucose at a level that appears only mildly abnormal. This compensatory hyperinsulinaemia is both the most important marker of metabolic risk and the most reliable predictor of progression to type 2 diabetes, yet it is almost never measured in Pakistani prediabetic patients. Dr. Zaar measures fasting insulin as a standard component of every metabolic assessment, because it tells the story that glucose alone cannot.
The FTO gene at Chromosome 16q12.2 reduces the metabolic buffer available between insulin resistance and overt diabetes in Pakistani patients through two simultaneous mechanisms. First, it impairs peripheral insulin sensitivity, increasing the compensatory insulin demand placed on pancreatic beta cells and accelerating their functional exhaustion. Second, it directly influences beta cell mass and function, reducing the pancreatic reserve available to sustain compensation as insulin resistance worsens. Pakistani patients carrying the FTO associated metabolic profile convert from prediabetes to type 2 diabetes at higher rates and over shorter time periods than Western populations at equivalent glucose levels. The arbitrary glucose thresholds that define prediabetes were established in Western populations and do not account for this accelerated Pakistani trajectory.
Prediabetes is the most reversible point on the diabetic spectrum, and complete reversal to normal metabolic function is achievable in the majority of Pakistani patients when the underlying insulin resistance is treated comprehensively rather than observed conservatively. Significant visceral fat reduction removes the primary inflammatory driver of insulin resistance. Insulin sensitivity restoration reduces the compensatory demand on beta cells, allowing them to recover function. Cortisol recalibration eliminates the overnight hepatic glucose overproduction that elevates fasting glucose. Dietary recalibration targeted at insulin secretion patterns rather than simple caloric restriction reduces the glucose and insulin load simultaneously. THE CHROMOSOME protocol achieves complete prediabetes reversal, normal fasting glucose, normal HbA1c, normal fasting insulin, in a significant proportion of patients treated at this stage. Every year of delay reduces the probability of reversal as beta cell exhaustion progresses.
Because the dietary advice given to Pakistani prediabetic patients, reduce sugar, eat less, walk more, addresses neither the compensatory hyperinsulinaemia nor the visceral inflammatory load that are driving the weight gain. High circulating insulin is the most powerful fat storage signal in the human body, it directs every available calorie into visceral fat storage while simultaneously blocking fat release for energy. A Pakistani prediabetic patient following dietary advice while their fasting insulin remains four times normal is fighting a biological force that willpower cannot overcome. The weight gain continues because the insulin remains high, and the insulin remains high because the insulin resistance driving it has never been treated. Dietary advice without insulin resistance treatment is not an intervention for Pakistani prediabetes. It is a delay in providing one.
The cardiovascular risk of prediabetes in Pakistani patients is substantially greater than global statistics suggest and begins accumulating from the earliest stages of insulin resistance, years before glucose reaches the prediabetic threshold. Compensatory hyperinsulinaemia directly promotes endothelial dysfunction, smooth muscle proliferation in arterial walls, and the platelet activation that underlies coronary thrombosis. Visceral fat derived inflammation accelerates atherosclerosis independently of blood glucose. Elevated triglycerides and suppressed HDL cholesterol, both driven by insulin resistance, complete a cardiovascular risk profile that Pakistani cardiologists treat with statins and antihypertensives while the metabolic origin goes unaddressed. Dr. Zaar treats prediabetes as a cardiovascular condition as much as a metabolic one, because the heart pays the price of insulin resistance long before the pancreas fails completely.
Chronic stress maintains cortisol at persistently elevated levels, stimulating hepatic glucose production continuously and reducing peripheral insulin sensitivity through direct cortisol receptor activation in muscle and adipose tissue. In Pakistani patients, the social, familial, and financial stressors of Pakistani life create a cortisol burden that operates as a continuous prediabetic driver independent of dietary patterns. The Pakistani patient who eats carefully but lives under chronic stress is still experiencing daily cortisol mediated glucose elevation and insulin demand that pushes progressively toward beta cell exhaustion. THE CHROMOSOME protocol addresses the cortisol dimension of prediabetes as a clinical priority, because in Pakistan, the stress axis is always part of the metabolic story.
Prediabetes in Pakistani women of reproductive age carries consequences that extend beyond individual metabolic health. Insulin resistance and compensatory hyperinsulinaemia in prediabetic Pakistani women drives androgen excess and PCOS, compromising fertility at the same stage of life when conception is most desired. Prediabetes significantly increases the risk of gestational diabetes in subsequent pregnancies, exposing both mother and child to the metabolic consequences of intrauterine glucose excess. Children born to prediabetic Pakistani mothers carry an elevated risk of obesity and metabolic syndrome from birth, perpetuating the metabolic trajectory across generations. And the FTO gene associated predisposition is heritable, meaning that untreated prediabetes in a Pakistani mother today creates metabolic vulnerability in her children tomorrow. Treating prediabetes comprehensively in Pakistani women of reproductive age is not only an individual health intervention. It is a generational one.